The role of maintenance treatment in advanced non-small-cell lung cancer: Reality or early second line?

Clinical Lung Cancer

Volumn 11, Issue 6, 2010, Pages 374-382

  Gridelli, Cesare ^a   Rossi, Antonio ^a   Maione, Paolo ^a   Ambrosio, Rita ^a   Barbato, Valentina ^a   Bareschino, Maria Anna ^a   Schettino, Clorinda ^a   Palazzolo, Giovanni ^b   Sacco, Paola Claudia ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b ULSS15   (Italy)

Author keywords

Duration of chemotherapy; Epidermal growth factor receptor; Erlotinib; Pemetrexed; Targeted therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM; TAXANE DERIVATIVE; VINBLASTINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78649247063     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.049     Document Type: Review

References (33)

1. Mountain C F. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710-7.
2. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer: stage IV: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007; 132:277S-89S.
3. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20:iv68-70.
4. Azzoli CG, Baker S, Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27:6251-66.
5. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63:1727-33.
6. Soon YY, Stockler MR, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009; 27:3277-83.
7. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer V.2.2010. Available at http://www.nccn.org/professionals/physician-gls/PDF/ nscl.pdf. Accessed: April 21, 2010.
8. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mito-mycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19:1336-43.
9. von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006; 95:966-73.
10. Park JO, Kim S-W, Ahn JS, et al. Phase II trial of two versus four additional cycles in patients who are non-progressive after two cycles of platinum-based chemotherapy and its clinical implications for future management of non-small cell lung cancer: a prospective randomized phase III trial by the Korean Cancer Study Group. J Clin Oncol 2007; 25:5233-9.
11. Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a West Japan Thoracic Oncology Group trial (WJTOG0203). J Clin Oncol 2010; 28:753-60.
12. Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:499-506.
13. Fidias PM, Dakhil SR, Lyss A P, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:591-8.
14. Buccheri G F, Ferrigno D, Curcio A, et al. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 1989; 63:428-32.
15. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small cell lung cancer. J Clin Oncol 2002; 20:1335-43.
16. Brodowicz T, Krakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase II trial. Lung Cancer 2006; 52:155-63.
17. Belani C P, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21:2933-9.
18. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-40.
19. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14:253-63.
20. Paz-Ares LG, Altug S, Vaury AT, et al. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. BMC Cancer 2010; 10:85
21. Belani C P, Waterhouse DM, Ghazal H, et al. Phase III study of maintenance gem-citabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28(15 suppl):540s (abstract 7506).
22. Rossi A, Galetta D, Gridelli C. Biological prognostic and predictive factors in lung cancer. Oncology 2009; 77:90-6.
23. John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009; 28:S14-23.
24. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11:521-9.
25. European Medicine Agency. Committee for medicinal products for human use (CHMP). Summary of opinion (post authorization): Tarceva. Available at http://www.ema.europa.eu/pdfs/human/opinion/TarcevaII-8608010en.pdf. Accessed: April 25, 2010.
26. Food and Drug Administration. Highlights of prescribing information: Tarceva. Available at http://www.accessdata.fda.gov/drugsat fda-docs/label/2010/ 021743s14s16lbl.pdf. Accessed: April 25, 2010.
27. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-55.
28. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-47.
29. Kabbinavar F F, Miller VA, Johnson BE, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28(15 suppl):544s (abstract 7526).
30. Johnson B, Miller V, Amler L, et al. Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advance. Eur J Cancer Supplements 2009; 7:5 (abstract 8LBA).
31. Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010; 28(15 suppl):540s (abstract 7507).
32. Gaafar R, Surmont V, Scagliotti G, et al. A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). J Clin Oncol 2010; 28(15 suppl):542s (abstract 7518).
33. Clinical trials endpoints for the approval of cancer drugs and biologics. Available at: http://www. fda.gov/cber/gdlns/clintrialend.htm. Accessed: February 19, 2010